The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The potential cost-effectiveness of a risk-based pancreatic cancer screening strategy in new-onset diabetes.
 
Naomi RM Schwartz
No Relationships to Disclose
 
Lynn McCormick Matrisian
Other Relationship - Abbvie (Inst); Allergan Foundation (Inst); Amgen Foundation (Inst); AngioDynamics (Inst); AstraZeneca (Inst); Baxter (Inst); Boston Biomedical (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Elstar Therapeutics (Inst); ERYTECH Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunovia (Inst); Interpace Diagnostics (Inst); Ipsen (Inst); Janssen Research & Development (Inst); Johnson & Johnson (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck Sharp & Dohme (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); SERVIER (Inst); Shire (Inst); Takeda (Inst); TriSalus Life Sciences (Inst); TYME (Inst)
 
Eva Shrader
Other Relationship - Abbvie (Inst); Allergan Foundation (Inst); Amgen Foundation (Inst); AngioDynamics (Inst); AstraZeneca (Inst); Baxter International Foundation (Inst); Boston Biomedical (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Elstar Therapeutics (Inst); ERYTECH Pharma (Inst); Genentech (Inst); GlaxoSmithKline Foundation (Inst); Halozyme (Inst); Immunovia (Inst); Interpace Diagnostics (Inst); Ipsen (Inst); Janssen Research & Development (Inst); Johnson & Johnson (Inst); Lilly (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); SERVIER (Inst); Shire (Inst); Takeda (Inst); TriSalus Life Sciences (Inst); TYME (Inst)
 
Ziding Feng
Patents, Royalties, Other Intellectual Property - I am one of the co-inventors for a biomarker panel for pancreatic cancer. The patent was filed by the UT MD Anderson Cancer Center and was licensed to to a company by the UT MD Anderson Cancer Center
 
Suresh Chari
No Relationships to Disclose
 
Joshua A. Roth
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Epigenomics
Research Funding - Bayer